tbuckley/cabot-search huggingface dataset:
Remembering the Hippocratic Oath in Surgical Training
Authors: Linwah Yip, Kelly L. McCoy, Sally E. Carty
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Improving the Rate of Translation of Tissue Engineering Products
Authors: Roza Vaez Ghaemi, Lim C. Siang, Vikramaditya G. Yadav
Journal: Advanced Healthcare Materials (2019)

Abstract Over 100 000 research articles and 9000 patents have been published on tissue engineering (TE) in the past 20 years. Yet, very few TE products have made their way to the market during the same period. Experts have proposed a variety of strategies to address the lack of translation of TE products. However, since these proposals are guided by qualitative insights, they are limited in scope and impact. Machine learning is utilized in the current study to analyze the entire body of patents that have been published over the past twenty years and understand patenting trends, topics, areas of application, and exemplifications. This analysis yields surprising and little‐known insights about the differences in research priorities and perceptions of innovativeness of tissue engineers in academia and industry, as well as aids to chart true advances in the field during the past twenty years. It is hoped that this analysis and subsequent proposal to improve translational rates of TE products will spur much needed dialogue about this important pursuit.
Infographic. A systematic review and meta-analysis of the effect of β-alanine supplementation on exercise capacity and performance
Authors: Bryan Saunders, Adam Virgile, Kirsty Jayne Elliott-Sale, Guilherme Giannini Artioli, Paul A Swinton, Eimear Dolan, Hamilton Roschel, Craig Sale, Bruno Gualano
Journal: British Journal of Sports Medicine (2019)

Carnosine (β-alanyl-L-histidine) is an abundant compound in skeletal muscle, suggesting it plays an important role during exercise, with a key physiological role considered to be intracellular pH regulation.1 Chronic β-alanine supplementation can increase muscle carnosine content when taken for several weeks,2 and studies have shown that supplementation between 4 and 24 weeks can improve high-intensity exercise capacity, with the gains in exercise associated with the increase in muscle carnosine content.3 4 Although several studies have demonstrated the efficacy of β-alanine supplementation as an ergogenic aid, there are a number of confounding factors that may modify its effect, including exercise …
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure
Authors: Elisabetta Degasperi, Angiola Spinetti, Andrea Lombardi, Simona Landonio, Maria Cristina Rossi, Luisa Pasulo, Pietro Pozzoni, Alessia Giorgini, Paolo Fabris, Antonietta Romano, Lorenzo Lomonaco, Massimo Puoti, Maria Vinci, Federico Gatti, Giada Carolo, Alessia Zoncada, Paolo Bonfanti, Francesco Paolo Russo, Alessio Aghemo, Alessandro Soria, Riccardo Centenaro, Franco Maggiolo, Pierangelo Rovere, Francesca Pasin, Veronica Paon, Giovanni Faggiano, Alessandro Vario, Glenda Grossi, Roberta Soffredini, Canio Carriero, Stefania Paolucci, Franco Noventa, Alfredo Alberti, Pietro Lampertico, Stefano Fagiuoli
Journal: Journal of Hepatology (2019)
Integrin inhibition as a potential target for invasive meningiomas.
Authors: Christian Mawrin, Elmar Kirches, Anette Wilisch-Neumann
Journal: Journal of Clinical Oncology (2013)

e22140 Background: Meningiomas are frequent intracranial tumors, which may show high rates of tumor recurrence after surgery. Additionally, a number of meningiomas show aggressive clinical behaviour with significant reduction of patient´s survival. In the present study, the impact of cilengitide, an integrin inhibitor, on migration, proliferation and radiosensitization of meningioma cells was evaluated. Methods: We analyzed integrin expression in tissue microarray samples and the anti-meningioma properties of cilengitide in vitro using different meningioma cell lines including pairs with knockdown of NF2, and tested the substance in subcutaneous and intracranial orthotopic nude mice models. Results: The predominantly expressed integrin in the tumor cells was αvβ5, while αvβ3 was mainly restricted to tumor blood vessels. One µM cilengitide was sufficient to significantly inhibit meningioma cell migration and invasion in vitro. On the other hand, even high doses of the drug resulted in only mildly reduced proliferation/survival of the cells, although the effects on cell survival were improved by irradiation. A daily dosage of up to 75 mg/kg did not affect tumor volumes in both mouse models. However, a combination of 75 mg/kg cilengitide daily and irradiation (2 x 5 Gy) led to a stronger reduction of MRI estimated tumor volumes in the intracranial model (67%, p&lt;0.01), as compared to the corresponding reduction reached by irradiation alone (55%, p&lt;0.05). Conclusions: These data show that the integrin inhibitor has mild cytostatic properties in meningioma cells, but strongly inhibits cell migration/invasion. In combination with radiotherapy it may help to further reduce meningioma tumor recurrence.
In Low-Value Care, Less Is (Not Always) More—Reply
Authors: Tim Badgery-Parker, Adam G. Elshaug
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Health‐related quality of life and long‐term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients
Authors: S. Ingen‐Housz‐Oro, A. Alves, A. Colin, R. Ouedraogo, R. Layese, F. Canoui‐Poitrine, O. Chosidow, A. Mekontso‐Dessap, P. Wolkenstein, N. Prost
Journal: British Journal of Dermatology (2019)

Few studies have investigated the global burden of sequelae and health‐related quality of life (HRQoL) for survivors of epidermal necrolysis (EN). To investigate the long‐term HRQoL for survivors of EN using validated instruments. We conducted a single‐centre study that enrolled patients who were admitted for EN between 2010 and 2017. HRQoL was assessed via phone interview using the Short Form (SF)‐36 questionnaire, Hospital Anxiety and Depression (HAD) scale, Impact of Event Scale‐Revised, and general quality‐of‐life outcomes, including EN‐specific sequelae. The primary outcome measure was the physical component summary (PCS) score of the SF‐36. In total, 57 survivors of EN [19 (33%) with intensive care unit (ICU) admission] were interviewed via telephone at a median of 3·6 years (1·9–6·1) after hospital discharge. The median PCS score was 0·44 SDs below that of the age‐ and sex‐matched reference population and was significantly lower for survivors of EN who were admitted to the ICU vs. those who were not [43·7 (28·7–49·3) vs. 51·2 (39·4–56·5), P = 0·042]. The proportion of patients with EN who had HAD‐anxiety score ≥ 8 or HAD‐depression score ≥ 5 was 54% and 21%, respectively. Physical and mental outcomes did not differ between patients with EN who were admitted to the ICU and survivors of septic shock. Reported EN‐specific sequelae were cutaneous (77%), ocular (70%), psychological (60%), dental/oral (49%), genital (30%) and respiratory (18%), with median intensity on a visual analogue scale. Our study confirms the major burden and long‐term impact of EN on quality of life for survivors and emphasizes the need for prolonged close follow‐up after the acute phase. What's already known about this topic? Long‐term sequelae have been reported in 90% of survivors of epidermal necrolysis (EN). Few studies have investigated the global burden of sequelae and health‐related quality of life (HRQoL) in survivors of EN. What does this study add? Survivors of EN, particularly those admitted to the intensive care unit, had poorer physical HRQoL than the French reference population but had comparable HRQoL to survivors of septic shock. Survivors of EN exhibited symptoms of anxiety, depression and post‐traumatic stress syndrome. The most frequent sequelae were cutaneous, ocular and psychological, with visual analogue scale scores of 5/10 and 6/10. These results confirm the burden of EN on quality of life.
Single institutional series of neuroendocrine tumours managed in the Australian capital territory.
Authors: Laeeq Malik, Yu Jo Chua, Nadeem Butt, Desmond Yip
Journal: Journal of Clinical Oncology (2012)

e14703 Background: Neuroendocrine tumours (NETs) have been regarded as indolent tumors with significantly variable clinical behavior. Limited information is available on long-term clinical outcome and clinically applicable prognostic factors.We performed a retrospective review of NETS managed in the Australian Capital Territory (ACT) over a 12-year period,with examination of epidemiology and various prognostic clinicopathologic factors. Methods: This multicenter analysis included patients in ACT and surrounding New South Wales treated with histologically proven neuroendocrine tumor (lung carcinoids excluded). The cases were identified from hospital databases. Data was analysed according to epidemiological, clinical and histopathological characteristics. Results: The cohort of 107 patients showed slight male predominance. Median age at diagnosis was 62 years and tumour size of 1.2 cm. The most common primary tumour site was jejunum/ileum (32%) followed by rectum (22%) and pancreas (11.2 %). Most patients had localised disease at initial diagnosis (n- 73/107 (68%). Distant metastases were seen in 32% (n-34/107) on initial staging with liver being most common site. Most patients were symptomatic at diagnosis while 22.4% cases were found incidentally. Second malignancies in particular of gastrointestinal origin were diagnosed in 33.6% (n-36/107). Surgical debulking was the most common treatment (59.8%) while 18% had multi-modality therapy. At a median followup of 25 months from diagnosis, 76 patients (78%) were still alive. Median time to first relapse was 15 months. 5 year survival rate was 75% for NETs originating from jejunum/ilieum on Kaplan-Meier analysis. Increasing age, tumor size, male gender, high histological grade, high Ki 67 index, raised plasma chromogranin A and urine 5 HIAA at the time of diagnosis were associated with shorter 5-year survival. Conclusions: The epidemiologic characteristics and long-term outcome in our series was comparable to reported studies from other centers. This analysis confirmed some important prognostic factors that could be considered for risk stratification and therapeutic management in patients with NETs.
<i>Notes from the Field:</i> Clinical <i>Klebsiella pneumoniae</i> Isolate with Three Carbapenem Resistance Genes Associated with Urology Procedures — King County, Washington, 2018
Authors: Kirsten Vannice, Eileen Benoliel, Kelly Kauber, Claire Brostrom-Smith, Patricia Montgomery, Meagan Kay, Maroya Walters, Michael Tran, Marisa D’Angeli, Jeff Duchin
Journal: MMWR Morbidity and Mortality Weekly Report (2019)
Phase I study of pemetrexed (P) plus gemcitabine (G) in advanced solid tumors (ST)
Authors: M. G. Fury, J. Larkin, S. R. Gerst, P. Sabbatini, J. Konner, M. Orlando, D. F. Tai, T. Goss, C. Aghajanian, M. L. Hensley
Journal: Journal of Clinical Oncology (2007)

14055 Background: P is active in multiple ST types, and preclinical data support P synergy with G. Methods: Eligible advanced ST patients (pts) with no prior P or G, no prior radiotherapy (RT) to ≡ 25% of the marrow, Karnofsky Performance Status ≡ 70%, and adequate organ function enrolled in cohorts (C) of 3, expanding to 6 if dose-limiting toxicity (DLT) occurred. P was given at 300 (C1), 400 (C2), 500 (C3) or 600 (C4) mg/m 2 followed by G at 1500 mg/m 2 q 14 days (d) without granulocyte-colony stimulating factor. Vitamin B12 and folate supplementation were given. Response was assessed by RECIST Results: 29 pts (median number prior regimens 2, range 1–5; 66% with prior RT) enrolled and are evaluable for safety; 23 are evaluable for response. There were no DLTs in C1. One pt in C2 was replaced after 1 cycle for progression of disease (PD). Among the next 6 pts, 2 had DLTs (1 G3 thrombocytopenia [TP] treatment delay; 1 neutropenic fever [NF]). C2-R (C2, Revised) re-opened after amendment permitting ≡ 2 prior cytotoxic regimens, no history of brain metastases/brain RT. C2-R enrolled 8 pts with 1 DLT (G3 TP with treatment delay) and 2 pts replaced (1 early PD, 1 no documented duration of neutropenia [NP]). C3 had 0/3 pts with DLT. C4 had 2/3 pts with DLTs (1 G4 hyponatremia; 1 herpes zoster-related treatment delay). C3 has been expanded to 5 of 6 planned patients, one with DLT (NF, G4 TP). Toxicities per cycle (n= 189 cycles, 29 patients): include NP-G3 (23%), G4 (14%); TP-G3 (2%); WBC-G3 (30%), G4 (4%); lymphopenia-G3 (11%), Hgb-G3 (4%); G3-NF (1%). 3/23 (13%) had objective partial responses (2 head and neck squamous cell cancer, HNSCC; 1 nasopharyngeal cancer, NPC), 4 stable disease (SD), 16 PD. (1 pt, no measurable disease at baseline; 5 pts, too early for response assesment). Conclusions: G + P is well-tolerated, and yields objective responses in HNSCC and NPC. C3 (P 500 mg/m 2 + G 1500 mg/m 2 q 14 d) was the phase II recommended dose in another phase I study of this regimen (Melemed ASCO 2005). Our final results will be available for ASCO 2007. No significant financial relationships to disclose.
Acute Pain Management in Patients Treated With Buprenorphine
Authors: Rachel Cooper, Rahul Vanjani, M. Catherine Trimbur
Journal: JAMA Internal Medicine (2019)

This Teachable Moment describes the case of a man in his 40s with a history of opioid use disorder in remission taking buprenorphine/naloxone who presented with a fifth distal phalanx fracture and underwent surgery, but had postoperative difficulty securing a prescription for buprenorphine/naloxone.
Expressions of KLF2 and chemokine receptor CCR7 in pulmonary adenocarcinoma.
Authors: Meiji Itakura, Masato Shingoji, Toshihiko Iizasa
Journal: Journal of Clinical Oncology (2012)

e21054 Background: Chemokines and chemokine receptors not only have the powerful ability in cancer metastasis and tumorigenesis, but also act as anti-tumorgenic ability. Lung Krueppel-like factor (LKLF, KLF2) is a member of the family of the Krueppel-like factors (KLFs). KLF2 was initially described as a lung-specific transcription factor. KLF2 is reported to regulate some malignant cells. We examined and evaluated the effect of KLF2 on pulmonary adenocarcinoma and the relationship of their mRNA expression with CCR7, EGFR and p53 genetical mutations in pulmonary adenocarcinoma. Methods: 120 patients of stage I to IV with pulmonary adenocarcinoma were included in this retrospective analysis. The expression of CCR7 and KLF2 mRNA expression in surgically resected pulmonary adenocarcinoma specimens were examined and evaluated the relation to prognosis, the effect of EGFR and p53 genetical mutations. Results: High mRNA expression of KLF2 in lung cancer patients indicated significantly good prognosis than the groups of low expressions (p= 0.0066, HR= 2.008, 95% CI of ratio 1.215 to 3.319). The expression of KLF2 mRNA had relationships with CCR7 mRNA expression in pulmonary adenocarcinoma. Moreover the mRNA expression of KLF2 in pulmonary adenocarcinoma specimens was influenced by the mutation of p53 mutation in lung cancer specimens. There was no significant difference within KLF2 mRNA expression quantities of EGFR mutation positive and negative group. Conclusions: We propose KLF2 as clinical good prognostic factors and that KLF2 has strong relation with CCR7 and p53 genetical mutation mRNA expression in pulmonary adenocarcinoma.
Uptake of Pineal Gland Visible on 18F-DOPA PET/CT With Last Generation of SiPM PET/CT
Authors: Pierre Decazes, Sébastien Hapdey, Olivier Humbert, Aude Marie-Cardine, Pierre Vera
Journal: Clinical Nuclear Medicine (2019)

Abstract A 17-year-old girl underwent an 18 F-DOPA brain PET/CT on a new high-resolution digital SiPM PET/CT (Vision600 Siemens) to explore a suspicion of recurrence of a pilocytic astrocytoma. This study showed a local recurrence, but a second intense focal uptake was visible above, more intense than striata. On fused MRI, this was the pineal gland considered as physiological. This physiological uptake, due to a pineal DOPA decarboxylase activity, has also been observed with this PET system in other patients with 18 F-DOPA to explore movement disorders. New high-resolution PET can show uptake of small structures by being less dependent to partial volume effect.
Abstract 15829: Periadvential Inflammation in Spontaneous Coronary Artery Dissection: Causal Role or Response to Injury?
Authors: Marios Margaritis, Mary Sheppard, Sarah Parsons, Jan Lukas Robertus, Aryan Vink, Nilesh Samani, David Adlam
Journal: Circulation (2018)

Introduction: Spontaneous Coronary Artery Dissection (SCAD) is a rare cause of acute coronary syndromes, which can manifest as sudden cardiac death. Histologically, SCAD is characterised by dissect...
DNA Aptamer Against Anti- Programmed Cell Death-1 (Anti-PD1-Apt) Induces Robust Anti-Leukemic Activity In Vitro and In Vivo Humanized NSG Mice with Myeloid Leukemia Xenografts
Authors: Santhana Gowri Thangavelu Devaraj, Lokesh Ganesh Lakshmana Rao, Youli Zu, Jenny Chang, Swami P. Iyer
Journal: Blood (2017)
Bispecific Fynomer-antibody fusion proteins targeting two epitopes on HER2.
Authors: Frederic Mourlane, Isabella Toller, Simon Brack, Dragan Grabulovski, Julian Bertschinger-Ehrler
Journal: Journal of Clinical Oncology (2012)

2575 Background: Fynomers are small binding proteins (7 kDa) derived from the SH3 domain of Fyn kinase. They can be engineered to yield specific and high-affinity binding domains to target proteins of interest. In the past, we have isolated Fynomers with excellent physico-chemical properties binding to 16 different antigens. One important application of the Fynomer technology represents the genetic fusion of a Fynomer to an antibody to provide bispecific fusion proteins. Methods: Using phage display technology we have isolated Fynomers binding to tumor-associated antigens. After genetic fusion of these Fynomers to antibodies of interest the resulting bispecific proteins were evaluated in vitro and in vivo for their antitumoral activity. Results: The fusion of Fynomers to the antibodies of interest did not alter the favorable biophysical properties of the antibodies. First, the Fynomer-antibody fusion proteins could be purified with the same high yields from the supernatant of transiently transfected CHO cells as the unmodified antibodies (in the range of 100 mg/L). Second, the purified fusion proteins were monomeric and showed no signs of aggregation even after four months of storage at 4 °C or -20 °C in PBS as determined by size exclusion chromatography. Third, the Fc-mediated effector functions of antibodies were not altered by their fusion with Fynomers. Antibody-dependent cellular cytotoxicity (ADCC) was maintained, and the affinity to the neonatal Fc-receptor (FcRn) was similar as observed for the unmodified antibody. In addition, the bispecific Fynomer-antibody fusion proteins demonstrated excellent growth inhibition of tumor cells in vitro and high efficacy in vivo in tumor xenograft mouse models. Conclusions: These encouraging preclinical results indicate that the bispecific Fynomer-antibody fusions have highly promising properties with a great potential for further preclinical and clinical development.
Associations of Th2, Th17, Treg cells, and IgA<sup>+</sup> memory B cells with atopic disease in children: The Generation R Study
Authors: Kirsten I. M. Looman, Evelien R. van Meel, Christina Grosserichter‐Wagener, Floor J. M. Vissers, Janice H. Klingenberg, Nicolette W. de Jong, Johan C. de Jongste, Suzanne G. M. A. Pasmans, Liesbeth Duijts, Menno C. van Zelm, Henriëtte A. Moll
Journal: Allergy (2019)

Abstract Background New insights into immune cells could contribute to treatment and monitoring of atopic disease. Because nongenetic factors shape the human immune system, we here studied these immune cells in a large cohort with atopic children with adjustment for prenatal and postnatal confounders. Methods Information on atopic dermatitis, inhalant‐ and food‐allergic sensitization, asthma lung function scores was obtained from 855 10‐year‐old children within the Generation R cohort. 11‐color flow cytometry was performed to determine CD27 + and CD27 − IgG + , IgE + and IgA + memory B cells, Th1, Th2, Th17, and Treg‐memory cells from venous blood. Associations between any atopic disease, the individual atopic diseases, and immune cell numbers were determined. Results Children with any atopic disease had higher Th2, Treg, Treg‐memory, and CD27 + IgA + memory B‐cell numbers compared to children without atopic disease. When studying the individual diseases compared to children without the individual diseases, children with atopic dermatitis, inhalant‐, and food‐allergic sensitization had higher memory Treg cell numbers 12.3% (95% CI 4.2; 21.0), (11.1% (95% CI 3.0; 19.8), (23.7% (95% CI 7.9; 41.8), respectively. Children with food‐allergic sensitization had higher total B and CD27 + IgA + memory B‐cell numbers (15.2% [95% CI 3.2; 28.7], 22.5% [95% CI 3.9; 44.3], respectively). No associations were observed between asthma and B‐ or T‐cell numbers. Conclusion Children with any atopic disease and children with inhalant‐ and food‐allergic sensitization or atopic dermatitis had higher circulating memory Treg cells, but not higher IgE + B‐cell numbers. The associations of higher Treg and CD27 + IgA + B‐cell numbers in children with food‐allergic sensitization are suggestive of TGF‐β‐mediated compensation for chronic inflammation.